By Fineline Cube 
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) to initiate a Phase II/III clinical trial evaluating its investigational anti-EGFR monoclonal antibody pimurutamab (HLX07) in combination with its approved anti-PD-1 therapy HanSiZhuang (serplulimab) and chemotherapy versus standard-of-care regimens in advanced squamous non-small cell lung cancer (sqNSCLC).
The global study will compare HLX07 + HanSiZhuang + chemo against two control arms:
- Placebo + HanSiZhuang + chemo
- Placebo + pembrolizumab + chemo
This marks Henlius’ first pivotal trial outside China and represents a strategic push to validate its novel EGFR/PD-1 dual-targeting approach in a competitive immuno-oncology landscape.
Asset Profiles & Development Status
| Molecule | Type | Status | Key Indications |
|---|---|---|---|
| Pimurutamab (HLX07) | Recombinant anti-EGFR humanized mAb | Phase Ib/II completed (advanced solid tumors); favorable safety with chemo | Investigational—designed for EGFR-expressing solid tumors |
| HanSiZhuang (serplulimab) | Anti-PD-1 mAb (innovative, independently developed) | Approved in China | sqNSCLC, nsqNSCLC, ES-SCLC, ESCC (all in combo with chemo) |
Trial Design & Strategic Rationale
- Patient Population: First-line advanced sqNSCLC (PD-L1 unselected)
- Primary Endpoint: Progression-free survival (PFS); secondary: overall survival (OS), objective response rate (ORR)
- Mechanistic Hypothesis: Dual blockade of EGFR-driven tumor proliferation and PD-1-mediated immune evasion may overcome resistance seen with monotherapy checkpoint inhibitors
- Competitive Context: Most EGFR/PD-1 combinations have struggled due to toxicity; HLX07’s humanized design aims for improved tolerability
Commercial & Global Expansion Implications
- China Foundation: HanSiZhuang generated RMB 3.2 billion (~USD 465M) in 2025, establishing Henlius as a top-tier domestic PD-1 player
- International Ambition: Australia serves as a gateway to global regulatory submissions (FDA, EMA); positive data could support filings in 2028
- Differentiation: Unlike biosimilar-focused peers, Henlius is advancing innovative combinations to capture premium pricing and partnership interest
- Pipeline Leverage: Success would validate HLX07 for expansion into head & neck, colorectal, and other EGFR+ cancers
Market Backdrop
Squamous NSCLC accounts for ~30% of NSCLC cases globally, with limited targeted options beyond immunotherapy ± chemo. Despite pembrolizumab’s dominance, median PFS remains <7 months, underscoring the need for more effective regimens.
Forward‑Looking Statements
This brief describes a planned clinical trial. Enrollment timelines, efficacy outcomes, and regulatory pathways remain subject to trial execution and data readouts.-Fineline Info & Tech